A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
暂无分享,去创建一个
S. Kapur | G. Remington | P. Seeman | R. Zipursky | P. Seeman | C. Jones | Corey Jones | C. S. Shammi | C. Shammi
[1] S. Kapur. Receptor Occupancy by Antipsychotics — Concepts and Findings , 2000 .
[2] S. Kapur,et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. , 2000, The American journal of psychiatry.
[3] L. Fabre,et al. Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. , 1999, The American journal of psychiatry.
[4] S. Kapur,et al. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. , 1999, The American journal of psychiatry.
[5] L. Farde,et al. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. , 1998, Journal of clinical psychopharmacology.
[6] C. Halldin,et al. Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain. , 1998, Journal of clinical psychopharmacology.
[7] Alan A. Wilson,et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. , 1998, The American journal of psychiatry.
[8] A. Puech,et al. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose‐ranging study vs. haloperidol , 1998 .
[9] S. Kapur,et al. Do loxapine plus cyproheptadine make an atypical antipsychotic? PET analysis of their dopamine D2 and serotonin2 receptor occupancy. , 1998, Archives of general psychiatry.
[10] P. Seeman,et al. Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors , 1998, Molecular Psychiatry.
[11] Christer Halldin,et al. A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients , 1997, Psychopharmacology.
[12] J. Peuskens,et al. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia , 1997, Acta psychiatrica Scandinavica.
[13] S. Kasper,et al. Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine , 1997, Psychopharmacology.
[14] Peter J Ell,et al. Limbic selectivity of clozapine , 1997, The Lancet.
[15] L. Arvanitis,et al. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo , 1997, Biological Psychiatry.
[16] S. Hirsch,et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. , 1997, Archives of general psychiatry.
[17] H. Freeman. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies , 1997, International clinical psychopharmacology.
[18] S. Kapur,et al. Reliability of a simple non-invasive method for the evaluation of 5-HT2 receptors using [18F]-setoperone PET imaging. , 1997, Nuclear medicine communications.
[19] R. Murray,et al. In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole – a 123I IBZM single photon emission tomography (SPET) study , 1997, Psychopharmacology.
[20] S. Kapur,et al. Serotonin-dopamine interaction and its relevance to schizophrenia. , 1996, The American journal of psychiatry.
[21] K. Yoo,et al. Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double‐blind placebo‐controlled study , 1995, International clinical psychopharmacology.
[22] C. Halldin,et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. , 1995, The American journal of psychiatry.
[23] R. Spitzer. Dsm-IV Casebook: A Learning Companion to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition , 1994 .
[24] H. Meltzer,et al. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. , 1993, The Journal of pharmacology and experimental therapeutics.
[25] G. Sedvall,et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.
[26] C Crouzel,et al. A Method for the In Vivo Investigation of the Serotonergic 5‐HT2 Receptors in the Human Cerebral Cortex Using Positron Emission Tomography and 18F‐Labeled Setoperone , 1990, Journal of neurochemistry.
[27] H. Meltzer,et al. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.
[28] T. Barnes. A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.
[29] C Crouzel,et al. [18F]setoperone: a new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo. , 1988, European journal of pharmacology.
[30] H. Hall,et al. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. , 1984, European journal of pharmacology.
[31] P. Seeman,et al. Neuroleptics have identical potencies in human brain limbic and putamen regions. , 1983, European journal of pharmacology.
[32] P. Seeman,et al. Antipsychotic drug doses and neuroleptic/dopamine receptors , 1976, Nature.
[33] G. Simpson,et al. A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.
[34] R. Tölle. Drug therapy for schizophrenia , 1966, Der Landarzt.
[35] S. Kapur,et al. Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects. , 1999, The American journal of psychiatry.
[36] M. Bergström,et al. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel®) in patients with schizophrenia , 1998, Psychopharmacology.
[37] J. Kane,et al. Drug therapy : schizophrenia , 1996 .
[38] S. Kay,et al. The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.